PubMed Health⌕ Search

PubMed · 9773255

Autoimmune hemolytic anemia.

Abstract

Six types of autoimmune hemolytic anemias have been described. Table 1 provides summary highlights for each type of AIHA. WAIHA accounts for the majority of cases, followed by CAIHA and DIAHA. In recent years, AIHA status post-BMT has been noted to occur more often than previously reported, particularly in T-cell-depleted graft recipients. The clinical presentation is diverse among the various types of AIHAs: WAIHA cases may require a complex treatment regimen if unstable hemolytic anemia is present, and often permanent remission is infrequent. In contrast, CAIHA in younger patients (status postinfection) is frequently asymptomatic and self-limiting. If AIHA is suspected in a patient with clinically significant presentation, it is important to communicate with the transfusion service since specific tests to confirm these diagnoses are not routinely done. Special procedures may be necessary to identify underlying rbc alloantibodies prior to transfusion. In a patient pre-operative for cardiopulmonary-bypass surgery, CAIHA antibody testing should be done. When found, pre-operative management may lessen the risk of serious consequences such as hemolysis, renal failure, and myocardial damage. AIHA associated in BMT recipients is frequently severe, and, in some cases may be refractory to treatment despite complex management strategies. Further studies are needed to acquire a better understanding of the pathogenesis of BMT-associated AIHA.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Hashimoto. 1998. Autoimmune hemolytic anemia.. https://doi.org/10.1007/bf02737638

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Management of cancer-associated thrombotic microangiopathy: what is the right approach?

A 49-year-old Caucasian woman presented with features suggestive of thrombotic microangiopathy (TMA). She did not respond to treatment with repeated plasma exchange and corticosteroids. A bone marrow biopsy revealed presence of metastatic carcinoma. A limited autopsy revealed presence of breast cancer with rib metastases. Though severe deficiency of von Willebrand factor-cleaving protease was initially proposed as a key pathogenetic factor for thrombotic thrombocytopenic purpura, subsequent studies involving patients with cancer-associated TMA did not find as severe a deficiency of von Willebrand factor-cleaving protease as is seen in idiopathic cases of thrombotic thrombocytopenic purpura. Here we address one approach of management of these patients with cancer-associated TMA.

Anemia, Hemolytic↗

A toxicogenomic approach revealed hepatic gene expression changes mechanistically linked to drug-induced hemolytic anemia.

A variety of pharmaceutical compounds causes hemolytic anemia as a significant adverse effect and this toxicity restricts the clinical utility of these drugs. In this study, we applied microarray technology to investigate hepatic gene expression changes associated with drug-induced hemolytic anemia and to identify potential biomarker genes for this hematotoxicity. We treated female Sprague-Dawley rats with two hemolytic anemia-inducing compounds: phenylhydrazine and phenacetin. Hepatic gene expression profiles were obtained using a whole-genome oligonucleotide microarray with pooled RNA samples from individual rats within each dose group and analyzed in comparison with hepatic histopathology, hematology, and blood chemistry data. We identified a small subset of genes that were commonly deregulated in all the severe hemolytic conditions, some of which were considered to be involved in hepatic events characteristic of hemolytic anemia, such as hemoglobin biosynthesis, heme metabolism, and phagocytosis. Among them, we selected six upregulated genes as putative biomarkers, and their expression changes from microarray measurements were confirmed by quantitative real-time PCR using RNAs from individual animals. They were Alas2, beta-glo, Eraf, Hmox1, Lgals3, and Rhced. Expression patterns of all these genes showed high negative and positive correlation against erythrocyte counts and total bilirubin levels in circulation, respectively, suggesting that these genes may be the potential biomarkers for hemolytic anemia. These findings indicate that drug-induced hemolytic anemia may be detected based on hepatic changes in the expression of a subset of genes that are mechanistically linked to the hematotoxicity.

Anemia, Hemolytic↗